Ritholtz Wealth Management reduced its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 42.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,351 shares of the biopharmaceutical company’s stock after selling 10,744 shares during the period. Ritholtz Wealth Management’s holdings in PTC Therapeutics were worth $930,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Allworth Financial LP purchased a new stake in shares of PTC Therapeutics in the 2nd quarter valued at $67,000. EverSource Wealth Advisors LLC raised its position in PTC Therapeutics by 16.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 151 shares during the period. Harbor Investment Advisory LLC bought a new stake in PTC Therapeutics in the second quarter worth $81,000. Jacobi Capital Management LLC bought a new stake in PTC Therapeutics in the third quarter worth $91,000. Finally, Quantbot Technologies LP bought a new stake in PTC Therapeutics in the second quarter worth $112,000.
PTC Therapeutics Stock Down 4.0%
Shares of NASDAQ:PTCT opened at $60.97 on Tuesday. The company has a 50-day moving average price of $63.95 and a 200-day moving average price of $70.20. PTC Therapeutics, Inc. has a 12 month low of $58.80 and a 12 month high of $90.87.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.76). The company had revenue of $357.81 million during the quarter, compared to the consensus estimate of $306.43 million. During the same quarter in the previous year, the firm earned $0.20 earnings per share. PTC Therapeutics’s revenue was up 69.6% compared to the same quarter last year. Equities analysts expect that PTC Therapeutics, Inc. will post 0.49 earnings per share for the current year.
PTC Therapeutics declared that its Board of Directors has initiated a share buyback plan on Tuesday, November 3rd that authorizes the company to buy back $500 million in shares. This buyback authorization authorizes the biopharmaceutical company to buy up to 9.8% of its stock through open market purchases. Share buyback plans are often a sign that the company’s management believes its shares are undervalued.
Wall Street Analyst Weigh In
PTCT has been the topic of a number of recent research reports. Cantor Fitzgerald raised their price objective on PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. Zacks Research lowered PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Royal Bank Of Canada lifted their price target on PTC Therapeutics from $75.00 to $77.00 and gave the stock a “sector perform” rating in a research note on Friday, October 30th. Finally, TD Cowen boosted their price objective on PTC Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, PTC Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $99.23.
Check Out Our Latest Research Report on PTCT
Insiders Place Their Bets
In other news, VP Mark Boulding sold 435 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total transaction of $27,909.60. Following the transaction, the vice president directly owned 105,272 shares of the company’s stock, valued at approximately $6,754,251.52. The trade was a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $59.61, for a total value of $149,025.00. Following the transaction, the director owned 1,291,594 shares of the company’s stock, valued at approximately $76,991,918.34. This represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 64,265 shares of company stock worth $4,412,399. 5.30% of the stock is currently owned by company insiders.
About PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Featured Stories
- Five stocks we like better than PTC Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
